4BBF

Aminoalkylpyrimidine Inhibitor Complexes with JAK2


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.00 Å
  • R-Value Free: 0.289 
  • R-Value Work: 0.229 
  • R-Value Observed: 0.232 

Starting Model: other
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Sar and in Vivo Evaluation of 4-Aryl-2-Aminoalkylpyrimidines as Potent and Selective Janus Kinase 2 (Jak2) Inhibitors

Forsyth, T.Kearney, P.C.Kim, B.G.Johnson, H.W.B.Aay, N.Arcalas, A.Brown, D.S.Chan, V.Chen, J.Du, H.Epshteyn, S.Galan, A.A.Huynh, T.P.Ibrahim, M.A.Kane, B.Koltun, E.Mann, G.Meyr, L.E.Lee, M.S.Lewis, G.L.Noguchi, R.T.Pack, M.Ridgway, B.H.Shi, X.Takeuchi, C.S.Zu, P.Leahy, J.W.Nuss, J.M.Aoyama, R.Engst, S.Gendreau, S.B.Kassees, R.Li, J.Lin, S.-H.Martini, J.-F.Stout, T.Tong, P.Woolfrey, J.Zhang, W.Yu, P.

(2012) Bioorg Med Chem Lett 22: 7653

  • DOI: https://doi.org/10.1016/j.bmcl.2012.10.007
  • Primary Citation of Related Structures:  
    4BBE, 4BBF

  • PubMed Abstract: 

    We report the discovery of a series of 4-aryl-2-aminoalkylpyrimidine derivatives as potent and selective JAK2 inhibitors. High throughput screening of our in-house compound library led to the identification of hit 1, from which optimization resulted in the discovery of highly potent and selective JAK2 inhibitors. Advanced lead 10d demonstrated a significant dose-dependent pharmacodynamic and antitumor effect in a mouse xenograft model. Based upon the desirable profile of 10d (XL019) it was advanced into clinical trials.


  • Organizational Affiliation

    Exelixis, Department of Drug Discovery, 169 Harbor Way, South San Francisco, CA 94083, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
TYROSINE-PROTEIN KINASE JAK2
A, B, C, D
298Homo sapiensMutation(s): 1 
EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for O60674 (Homo sapiens)
Explore O60674 
Go to UniProtKB:  O60674
PHAROS:  O60674
GTEx:  ENSG00000096968 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO60674
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
O19 PDBBind:  4BBF IC50: 2.2 (nM) from 1 assay(s)
BindingDB:  4BBF IC50: min: 2.2, max: 695 (nM) from 3 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.00 Å
  • R-Value Free: 0.289 
  • R-Value Work: 0.229 
  • R-Value Observed: 0.232 
  • Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 68.946α = 75.53
b = 76.008β = 67
c = 88.179γ = 63.04
Software Package:
Software NamePurpose
REFMACrefinement
d*TREKdata reduction
DTSCALEAVERAGEdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

  • Released Date: 2012-11-21 
  • Deposition Author(s): Li, J.

Revision History  (Full details and data files)

  • Version 1.0: 2012-11-21
    Type: Initial release
  • Version 1.1: 2012-12-19
    Changes: Database references
  • Version 1.2: 2017-06-28
    Changes: Data collection
  • Version 1.3: 2024-05-01
    Changes: Data collection, Database references, Derived calculations, Other, Refinement description